title: Past, present and future targets for immunotherapy in ovarian cancer.
abstract: Ovarian cancer is the leading cause of death from gynecologic malignancy in the US. Treatments have improved with conventional cytotoxic chemotherapy and advanced surgical techniques but disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune system and its ability to recognize and eliminate microscopic disease is paramount in preventing recurrence. Ovarian cancer immunotherapy is targeting tumors through active, passive and adoptive approaches. The goal of immunotherapy is to balance the activation of the immune system against cancer while preventing the potential for tremendous toxicity elicited by immune modulation. In this paper we will review the different immunotherapies available for ovarian cancer as well as current ongoing studies and potential future directions.
authors.affiliation: Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.
authors.forename: Carlton L
authors.initials: CL
authors.lastname: Schwab
authors.forename: Diana P
authors.initials: DP
authors.lastname: English
authors.forename: Dana M
authors.initials: DM
authors.lastname: Roque
authors.forename: Monica
authors.initials: M
authors.lastname: Pasternak
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Santin
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy / Q000639:trends; D008213:Lymphocyte Activation; D058990:Molecular Targeted Therapy; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D012008:Recurrence
keywords: CA125; EpCAM; NY-ESO-1; WT-1; adoptive transfer; mesothelin; ovarian cancer; p53; tumor associated antigens; tumor vaccines